CodeMap® 
150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


2023 Printed Publications Early Bird Sale on Now through August 31, 2022!



User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule

2022
2021

Physician Fee Schedule

2022
2021

OPPS Fee Schedule

2022-July
2022-April

ASC Fee Schedule

2022-July
2022-April

APC Codes

2022-July
2022-April

DRG Codes

2022
2021

ASP Drug Pricing Files

July 2022
April 2022


CMS Transmittals



CodeMap® LCD-L38816

 

Printer Friendly Version

L38816
LCD for MolDX: Minimal Residual Disease Testing for Cancer (L38816)
See related Articles:
A58456-Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers
A58954-Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer
A58997-Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

Contractor Information

Contractor Name: Noridian Healthcare Solutions, LLC - Full list of policies of this Medicare Contractor

Contractor Number: 02102

Contractor Type: MAC B

LCD Information

LCD ID Number: L38816 Status: A-Approved

LCD Title: MolDX: Minimal Residual Disease Testing for Cancer

Geographic Jurisdiction: Alaska Other Jurisdictions

Original Determination Effective Date: 01/02/2022

Original Determination Ending Date:

Revision Effective Date:

Revision End Date:

CMS National Coverage Policy:

Title XVIII of the Social Security Act, §1862(a)(1)(A). Allows coverage and payment for only those services that are considered to be reasonable and necessary.

42 Code of Federal Regulations (CFR) 410.32(a). Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests, §80.1.1 Certification Changes

National Coverage Determination (NCD) 90.2, which allows contractors to cover next generation sequencing tests as a diagnostic laboratory test for patients with cancer in specific circumstances


Sorry, you need to login or register to view additional sections of this Medicare policy.

--
*
All information on this web site is compiled directly from information obtained from the Center for Medicare and Medicaid Services (CMS) and from its Contractors.

CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this web site. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

No part of this web page or data displayed may be redistibuted or used without the express written consent of Wheaton Partners, LLC.

08/08/2022 03:36:53 18.204.56.185


CodeMap® is a Registered Trademark of Wheaton Partners, LLC.